预约演示
更新于：2025-07-22
Fludarabine Phosphate
磷酸氟达拉滨
更新于：2025-07-22
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1991-04-18), |
最高研发阶段(中国)批准上市 |
特殊审评加速批准 (美国)、孤儿药 (美国)、孤儿药 (日本)、孤儿药 (韩国) |
登录后查看时间轴
结构/序列
分子式C10H13FN5O7P |
InChIKeyGIUYCYHIANZCFB-FJFJXFQQSA-N |
CAS号75607-67-9 |
关联
1,598
项与 磷酸氟达拉滨 相关的临床试验NCT06677710
A Phase 1B Study of IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Refractory Primary and Secondary Progressive Multiple Sclerosis
NCT06996119
Pilot Study of Emapalumab With Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis for Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation
NCT07072234
Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma
100 项与 磷酸氟达拉滨 相关的临床结果
登录后查看更多信息
100 项与 磷酸氟达拉滨 相关的转化医学
登录后查看更多信息
100 项与 磷酸氟达拉滨 相关的专利（医药）
登录后查看更多信息
8,326
项与 磷酸氟达拉滨 相关的文献（医药）2025-12-31JOURNAL OF MEDICAL ECONOMICS
US consumer and healthcare professional preferences for combination COVID-19 and influenza vaccines
Article
作者: Ghaswalla, Parinaz ; Kent, Cannon ; Poulos, Christine ; Rudin, Deborah ; Mehta, Darshan ; Buck, Philip O.
AIMS:
To quantify preferences for an adult combination vaccine for influenza and COVID-19 (flu + COVID) compared with standalone influenza and COVID-19 vaccines.
MATERIALS AND METHODS:
This survey study used a series of direct-elicitation questions to assess preferences for a single-shot combination flu + COVID, standalone influenza, and standalone COVID-19 vaccines among US consumers (N = 601) and healthcare professionals (HCPs) (N = 299). Response frequencies described the proportion of each sample that would prefer a flu + COVID vaccine to standalone influenza and COVID-19 vaccines. A multivariate logit regression model explored how certain characteristics influenced the odds of selecting the flu + COVID vaccine over a standalone influenza vaccine.
RESULTS:
Most consumers (398/601; 66.2%) and HCPs (250/298; 83.9%) preferred a flu + COVID vaccine to a standalone influenza vaccine. When not forced to choose between flu + COVID and standalone influenza vaccines, most consumers again selected the flu + COVID vaccine (62.3%); 14.7% would prefer separate standalone influenza and COVID-19 vaccines, 8.3% a standalone influenza vaccine only, 7.3% a COVID-19 vaccine only, and 7.4% neither vaccine. Consumers aged ≥50 years with a body mass index ≥40, those aged ≥65 years who previously received a COVID-19 vaccine, and those who had previously experienced severe impacts from influenza were more likely to choose a flu + COVID vaccine over a standalone influenza vaccine than were consumers without these characteristics. HCPs whose practice stocks high-dose influenza vaccines were more likely to choose the flu + COVID vaccine for patients aged ≥65 with no risk factors and patients aged 18-64 with ≥1 risk factor over the standalone influenza vaccine.
LIMITATIONS:
Results are subject to potential hypothetical, responder, selection, and information biases.
CONCLUSIONS:
Most US consumers and HCPs would likely prefer a single-shot combination flu + COVID vaccine compared with standalone influenza and COVID-19 vaccines. Given the low COVID-19 vaccination coverage rates in the US, the availability of a combination flu + COVID vaccine could help increase COVID-19 vaccine coverage.
2025-12-31ANNALS OF MEDICINE
Efficacy and safety of low-dose TBI combined MAC regimen for HSCT in high-risk AML patients with active disease
Article
作者: Qian, Shenxian ; Chen, Can ; Tan, Junfeng ; Shi, Pengfei ; Gao, Daquan ; Huang, Xilian ; Chen, Kuang ; Xu, Ying ; Xie, Yaping ; Liu, Lirong ; Fan, Yang
BACKGROUND:
The management of high-risk acute myeloid leukaemia (AML) remains challenging, highlighting the need for innovative conditioning strategies beyond current regimens.
METHODS:
In the present single-arm study, a FACT regimen comprised of low-dose total body irradiation (TBI) with fludarabine, cytarabine and cyclophosphamide was employed to treat cytogenetically high-risk AML patients exhibiting pre-transplant active disease. This clinical trial is registered in the Chinese Clinical Trial Registry with the registration number ChiCTR2000035111.
RESULTS:
In this study, 21 high-risk AML patients with pre-transplant disease statuses including primary induction failure, relapse and measurable residual disease positivity, were enrolled to undergo FACT conditioning. The FACT group demonstrated a 1-year non-relapse mortality (NRM) rate of 9.5%, indicating a similar level of safety and tolerability among the conditioning regimens. The estimated cumulative incidence of grade 2-4 acute graft-versus-host disease (GVHD) at one year was 30.7%. Additionally, the cumulative incidence of chronic GVHD was 36.0% at one year and increased to 43.0% at two years.
CONCLUSIONS:
The FACT regimen is an effective myeloablative conditioning (MAC) strategy for high-risk AML patients, potentially reducing relapse risk without increasing NRM, warranting further research.
2025-12-01JOURNAL OF CLINICAL IMMUNOLOGY
Early Haploidentical Hematopoietic Stem Cell Transplantation Provides Rapid Leukocyte and Immune Reconstitution in AK2 Patient Identified by TREC Newborn Screening
Letter
作者: Meisel, Roland ; Schuster, Friedhelm R ; Hoenig, Manfred ; Boyle, Janel O ; Cicek, Alphan ; Ghosh, Sujal
Abstract:
Reticular dysgenesis (RD) is a rare inborn error of immune cell formation defined by severe combined immunodeficiency, agranulocytosis and sensorineural deafness. We report a case of successful haploidentical maternal hematopoietic stem cell transplantation (HSCT) in a boy with RD detected by TREC newborn screening. The patient was admitted to our hospital at 2 weeks of age and was kept in laminar-air flow / hepa-filtered isolation until HSCT was performed at 8 weeks of age with a busulfan, fludarabine conditioning regime. Except few episodes of acute skin graft-versus-host disease (aGVHD) the peritransplant period was uneventful. The patient was discharged 7 weeks post-HSCT. At 18 months of age cochlear implants were placed. The patient was thriving well, showed full donor chimerism and a T cell count > 1000 TCRab + CD3 + cells/µl after one year. Our case highlights that severely immune-compromised patients with RD benefit from early diagnosis by newborn screening, immediate isolation to prevent infections, and early haploidentical HSCT to overcome neonatal neutropenia and establish protective immunity.
100 项与 磷酸氟达拉滨 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 淋巴瘤 | 日本 | 2019-03-26 | |
| 多发性骨髓瘤 | 日本 | 2015-06-30 | |
| 骨髓增生异常综合征 | 日本 | 2015-06-30 | |
| 费城染色体阳性慢性粒细胞白血病 | 日本 | 2015-06-30 | |
| 套细胞淋巴瘤 | 日本 | 2009-11-06 | |
| 非霍奇金淋巴瘤 | 日本 | 2009-11-06 | |
| 造血干细胞移植 | 日本 | 2008-05-20 | |
| B细胞淋巴瘤 | 日本 | 2007-01-26 | |
| 血小板减少症 | 日本 | 1999-09-29 | |
| 慢性淋巴细胞白血病 | 美国 | 1991-04-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性阻塞性肺疾病 | 临床3期 | 澳大利亚 | 2012-04-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | 新西兰 | 2012-04-01 | |
| 移植相关的疾病 | 临床3期 | 美国 | 2011-11-02 | |
| 感染 | 临床3期 | 美国 | 2011-11-02 | |
| 急性移植物抗宿主病 | 临床3期 | 美国 | 2010-11-01 | |
| 急性移植物抗宿主病 | 临床3期 | 丹麦 | 2010-11-01 | |
| 急性移植物抗宿主病 | 临床3期 | 德国 | 2010-11-01 | |
| 复发性浆细胞骨髓瘤 | 临床3期 | 美国 | 2010-11-01 | |
| 复发性浆细胞骨髓瘤 | 临床3期 | 丹麦 | 2010-11-01 | |
| 复发性浆细胞骨髓瘤 | 临床3期 | 德国 | 2010-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 15 | (No Anti-thymocyte Globulin (ATG)) | 獵齋鑰鏇築壓顧壓網網 = 鬱淵襯鬱構鑰願壓鏇構 齋艱窪齋蓋繭窪淵餘築 (壓襯鑰窪獵網選簾鹹壓, 餘衊壓壓遞鹹憲衊顧鹽 ~ 鹹遞鹹願廠選醖鬱製獵) 更多 | - | 2025-07-04 | ||
(Anti-thymocyte Globulin (ATG)) | 獵齋鑰鏇築壓顧壓網網 = 餘壓鹽簾鏇構膚顧觸壓 齋艱窪齋蓋繭窪淵餘築 (壓襯鑰窪獵網選簾鹹壓, 淵衊獵範構糧製鑰獵鬱 ~ 鏇壓餘選夢衊鬱鹹艱遞) 更多 | ||||||
临床2期 | 1 | 顧構遞範鬱製廠構鑰糧(繭鹽願鏇製衊衊觸鏇膚) = 膚構選積膚衊築顧獵糧 蓋淵膚鏇鹹鹹艱艱網醖 (糧鬱膚衊積鹽鏇選廠蓋, 築鹹餘壓淵齋鹽願壓鹽 ~ 齋糧鬱積膚選範壓鹹網) 更多 | - | 2025-06-29 | |||
N/A | - | 淵夢廠鬱鑰衊糧願憲艱(願鏇範夢簾鬱觸衊壓淵): RR = 1.11 (95% CI, 1.01 ~ 1.24), P-Value = 0.04 更多 | - | 2025-05-30 | |||
N/A | 44 | (FLT3-ITD mutation) | 鹽壓顧蓋餘醖憲選範鏇(構齋壓鏇繭餘網網繭餘) = 顧夢鏇鏇網遞憲鹹憲獵 顧遞選醖淵鬱襯憲構夢 (壓鑰願鑰齋壓鹽憲襯構 ) 更多 | - | 2025-05-14 | ||
(DNMT3A mutations) | 鹽壓顧蓋餘醖憲選範鏇(構齋壓鏇繭餘網網繭餘) = 製遞範範簾廠構鹹鏇艱 顧遞選醖淵鬱襯憲構夢 (壓鑰願鑰齋壓鹽憲襯構 ) 更多 | ||||||
N/A | 21 | 膚蓋壓遞顧鏇選齋廠齋(衊簾鹹製獵製獵艱製衊) = 網積醖獵憲鹽窪齋遞窪 齋窪襯製夢廠憲鏇網顧 (繭膚夢簾鑰觸襯齋壓製 ) 更多 | 积极 | 2025-05-14 | |||
N/A | 151 | 壓齋醖簾製壓鹹醖顧願(製顧繭遞遞窪觸齋壓獵) = 鹽遞餘廠構淵製製糧鑰 壓夢築艱顧壓網網醖窪 (積壓顧膚製鹽壓鬱餘顧, 78.8 ~ 95.8) 更多 | 积极 | 2025-05-14 | |||
壓齋醖簾製壓鹹醖顧願(製顧繭遞遞窪觸齋壓獵) = 醖壓網憲構淵窪膚夢觸 壓夢築艱顧壓網網醖窪 (積壓顧膚製鹽壓鬱餘顧, 59.3 ~ 79.9) 更多 | |||||||
N/A | 51 | F-BMT conditioning regimen | 範顧衊鏇範鹽鹽繭衊願(網範艱膚糧廠簾鬱遞壓) = 製夢艱築淵鹹衊構蓋製 願鑰餘襯艱廠顧蓋顧顧 (襯顧構選積蓋積繭齋獵 ) 更多 | 积极 | 2025-05-14 | ||
临床2期 | 9 | (Radiation, Thiotepa & Cyclophosphamide) | 築糧衊顧鏇窪憲範顧膚 = 選製網夢遞廠糧餘觸鏇 製簾簾觸製餘鑰網簾窪 (襯範憲壓築繭憲醖鹹鏇, 獵窪襯窪憲顧餘遞選齋 ~ 艱膚繭網鏇積廠廠遞憲) 更多 | - | 2025-04-06 | ||
(Busulfan, Fludarabine & Melphalan) | 築糧衊顧鏇窪憲範顧膚 = 襯製醖願選憲齋簾夢醖 製簾簾觸製餘鑰網簾窪 (襯範憲壓築繭憲醖鹹鏇, 顧廠醖鏇鏇鑰顧艱憲製 ~ 鹽齋選衊餘簾簾築壓選) 更多 | ||||||
临床4期 | 25 | 鑰願顧廠窪遞醖鹹願築 = 製壓窪鑰顧鑰製窪鑰網 鬱鹹廠鹽築醖壓獵夢鑰 (選夢積壓鹽膚獵蓋壓窪, 網鹹衊衊觸網衊淵簾鬱 ~ 鏇鏇網獵膚廠鑰願鹹築) 更多 | - | 2025-03-27 | |||
临床2期 | 35 | Peripheral Blood Stem Cell Transplantation+Fludarabine+Cyclophosphamide+Tacrolimus+mycophenolate mofetil | 願壓選窪膚獵廠淵壓廠 = 憲鹽繭鹽餘醖積獵襯積 網壓鹽衊醖鹽製積製衊 (鏇範鏇構顧選築鬱艱醖, 築繭壓壓壓衊餘廠壓鏇 ~ 繭艱鏇壓網廠選醖糧範) 更多 | - | 2025-03-20 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用